PolyPid (PYPD) News Today $3.30 +0.11 (+3.45%) As of 01/17/2025 03:59 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period PolyPid Regains Nasdaq Compliance with Private Placement BoostJanuary 17, 2025 | tipranks.comPolyPid (NASDAQ:PYPD) Stock Quotes, Forecast and News SummaryDecember 26, 2024 | benzinga.comPolyPid price target lowered to $11 from $14 at H.C. WainwrightDecember 26, 2024 | markets.businessinsider.comPolyPid’s SHIELD II Trial Progress and Financial Stability Justify Buy RatingDecember 25, 2024 | markets.businessinsider.comPolyPid announces DSMB recommendation to continue Phase 3 D-PLEX studyDecember 24, 2024 | markets.businessinsider.comPolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 MillionDecember 23, 2024 | globenewswire.comPolyPid’s Strategic Advancements and Clinical Progress: A Buy RecommendationDecember 16, 2024 | markets.businessinsider.comPolyPid announces research, development collaboration with ImmunoGenesisDecember 12, 2024 | markets.businessinsider.comPolyPid (PYPD) Gets a Buy from Craig-HallumDecember 12, 2024 | markets.businessinsider.comPolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer ImmunotherapyDecember 11, 2024 | globenewswire.comPolyPid Ltd.: PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-ComplianceNovember 30, 2024 | finanznachrichten.dePolyPid receives noncompliance notification from NasdaqNovember 29, 2024 | markets.businessinsider.comPolyPid Faces Nasdaq Non-Compliance ChallengeNovember 29, 2024 | tipranks.comPolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-ComplianceNovember 29, 2024 | globenewswire.comPolyPid (PYPD) Gets a Hold from BarclaysNovember 19, 2024 | markets.businessinsider.comPositive Indicators and Financial Stability Support Roy Buchanan’s Optimistic Outlook on PolyPid’s StockNovember 16, 2024 | markets.businessinsider.comPolyPid Reports Q3 Results Amid SHIELD II Trial ProgressNovember 15, 2024 | markets.businessinsider.comPolyPid Announces SHIELD II Trial Progress and FinancialsNovember 14, 2024 | markets.businessinsider.comPolyPid Ltd. (PYPD) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | seekingalpha.comPolyPid (PYPD) Receives a Buy from Craig-HallumNovember 12, 2024 | markets.businessinsider.comPolyPid Announces $8.25 Million Share Sale PlanNovember 9, 2024 | markets.businessinsider.comPolyPid to Participate in the Craig-Hallum 15th Annual Alpha Select ConferenceNovember 7, 2024 | globenewswire.comCraig-Hallum bullish on PolyPid, initiates with a BuyNovember 6, 2024 | markets.businessinsider.comCraig-Hallum Initiates Coverage of PolyPid (PYPD) with Buy RecommendationNovember 6, 2024 | msn.comPolyPid to Report Third Quarter 2024 Financial Results and Operational Highlights on November 13, 2024October 30, 2024 | globenewswire.comRosalind Advisors, Inc. Reduces Stake in PolyPid LtdOctober 24, 2024 | finance.yahoo.comPolyPid announces publication in IJS on Phase 3 SHIELD I trial of D-PLEX100October 22, 2024 | markets.businessinsider.comPolyPid Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ in Prevention of Surgical Site Infections in Abdominal Colorectal SurgeryOctober 21, 2024 | globenewswire.comPolyPid retains stock target, buy rating on positive trial enrollment updateOctober 4, 2024 | investing.comPolyPid completes enrollment for phase 3 trialOctober 3, 2024 | uk.investing.comBuy Rating Affirmed for PolyPid on D-PLEX’s Positive Trial Milestones and Commercial ProspectsOctober 3, 2024 | markets.businessinsider.comPolyPid Buy Rating Affirmed: Promising Clinical Trials and Solid Financial OutlookOctober 2, 2024 | markets.businessinsider.comPolyPid Announces Last Patient In for Planned Unblinded Interim Analysis in the Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site InfectionsOctober 1, 2024 | globenewswire.comPolyPid to Participate in Three Upcoming Fall Investor ConferencesSeptember 3, 2024 | globenewswire.comPolyPid (PYPD) Receives a Hold from BarclaysAugust 20, 2024 | markets.businessinsider.comPolyPid Ltd (PYPD) Q2 2024 Earnings Call TranscriptAugust 16, 2024 | seekingalpha.comBuy Rating Affirmed for PolyPid Amidst Strong Trial Progress and Robust Financial PositionAugust 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for PolyPid on D-PLEX Clinical Progress and Potential Early ApprovalAugust 16, 2024 | markets.businessinsider.comPolyPid Ltd. (NASDAQ:PYPD) Q2 2024 Earnings Call TranscriptAugust 16, 2024 | insidermonkey.comPolyPid Provides Corporate Update and Reports Second Quarter 2024 Financial ResultsAugust 14, 2024 | finance.yahoo.comPolyPid secures $14 million in private placementAugust 4, 2024 | investing.comPolyPid Announces Private Placement for Up to $14 Million in Gross ProceedsAugust 1, 2024 | globenewswire.comPolyPid to Report Second Quarter 2024 Financial Results and Operational Highlights on August 14, 2024July 31, 2024 | globenewswire.comPolyPid to Host Virtual KOL Event on June 17, 2024, and Provide an Update on the Company's Ongoing D-PLEX₁₀₀ Phase 3 TrialJune 10, 2024 | globenewswire.comEarnings call: PolyPid reports progress in D-PLEX100 trial, eyes expansionMay 12, 2024 | investing.comPolyPid Ltd. (NASDAQ:PYPD) Q1 2024 Earnings Call TranscriptMay 10, 2024 | finance.yahoo.comBuy Rating Affirmed for PolyPid on D-PLEX Progress and Solid Financial FootingMay 9, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: PolyPid (PYPD) and Cartesian Therapeutics (RNAC)May 8, 2024 | markets.businessinsider.comPYPD Stock Earnings: PolyPid Beats EPS for Q1 2024May 8, 2024 | investorplace.comPolyPid Provides Corporate Update and Reports First Quarter 2024 Financial ResultsMay 8, 2024 | globenewswire.com Get PolyPid News Delivered to You Automatically Sign up to receive the latest news and ratings for PYPD and its competitors with MarketBeat's FREE daily newsletter. Email Address PYPD Media Mentions By Week PYPD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PYPD News Sentiment▼-0.500.49▲Average Medical News Sentiment PYPD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PYPD Articles This Week▼11▲PYPD Articles Average Week Get PolyPid News Delivered to You Automatically Sign up to receive the latest news and ratings for PYPD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Alpha Pro Tech News Titan Medical News Cytosorbents News Inovio Pharmaceuticals News Apyx Medical News iCAD News Lucid Diagnostics News DIH Holding US News CollPlant Biotechnologies News Bellevue Life Sciences Acquisition News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PYPD) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PolyPid Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share PolyPid With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
